Zevra Therapeutics (ZVRA) Competitors $7.26 +0.03 (+0.41%) Closing price 04:00 PM EasternExtended Trading$7.30 +0.04 (+0.55%) As of 04:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ZVRA vs. ADPT, RXRX, ARQT, TVTX, DYN, BEAM, SRPT, IMCR, MESO, and APGEShould you be buying Zevra Therapeutics stock or one of its competitors? The main competitors of Zevra Therapeutics include Adaptive Biotechnologies (ADPT), Recursion Pharmaceuticals (RXRX), Arcutis Biotherapeutics (ARQT), Travere Therapeutics (TVTX), Dyne Therapeutics (DYN), Beam Therapeutics (BEAM), Sarepta Therapeutics (SRPT), Immunocore (IMCR), Mesoblast (MESO), and Apogee Therapeutics (APGE). These companies are all part of the "pharmaceutical products" industry. Zevra Therapeutics vs. Its Competitors Adaptive Biotechnologies Recursion Pharmaceuticals Arcutis Biotherapeutics Travere Therapeutics Dyne Therapeutics Beam Therapeutics Sarepta Therapeutics Immunocore Mesoblast Apogee Therapeutics Zevra Therapeutics (NASDAQ:ZVRA) and Adaptive Biotechnologies (NASDAQ:ADPT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, analyst recommendations, earnings, media sentiment and risk. Do institutionals and insiders hold more shares of ZVRA or ADPT? 35.0% of Zevra Therapeutics shares are held by institutional investors. Comparatively, 99.2% of Adaptive Biotechnologies shares are held by institutional investors. 2.4% of Zevra Therapeutics shares are held by insiders. Comparatively, 6.4% of Adaptive Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is ZVRA or ADPT more profitable? Zevra Therapeutics has a net margin of 4.33% compared to Adaptive Biotechnologies' net margin of -59.07%. Adaptive Biotechnologies' return on equity of -60.93% beat Zevra Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Zevra Therapeutics4.33% -112.40% -37.67% Adaptive Biotechnologies -59.07%-60.93%-23.03% Does the media refer more to ZVRA or ADPT? In the previous week, Zevra Therapeutics and Zevra Therapeutics both had 6 articles in the media. Zevra Therapeutics' average media sentiment score of 1.27 beat Adaptive Biotechnologies' score of 1.15 indicating that Zevra Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zevra Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Adaptive Biotechnologies 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better valuation and earnings, ZVRA or ADPT? Zevra Therapeutics has higher earnings, but lower revenue than Adaptive Biotechnologies. Zevra Therapeutics is trading at a lower price-to-earnings ratio than Adaptive Biotechnologies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZevra Therapeutics$62.02M6.57-$105.51M-$0.21-34.57Adaptive Biotechnologies$205.22M9.58-$159.49M-$0.82-15.74 Do analysts rate ZVRA or ADPT? Zevra Therapeutics presently has a consensus target price of $23.71, suggesting a potential upside of 226.64%. Adaptive Biotechnologies has a consensus target price of $12.38, suggesting a potential downside of 4.14%. Given Zevra Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Zevra Therapeutics is more favorable than Adaptive Biotechnologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zevra Therapeutics 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.89Adaptive Biotechnologies 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.88 Which has more risk & volatility, ZVRA or ADPT? Zevra Therapeutics has a beta of 1.56, meaning that its share price is 56% more volatile than the S&P 500. Comparatively, Adaptive Biotechnologies has a beta of 1.93, meaning that its share price is 93% more volatile than the S&P 500. SummaryAdaptive Biotechnologies beats Zevra Therapeutics on 8 of the 15 factors compared between the two stocks. Get Zevra Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ZVRA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZVRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZVRA vs. The Competition Export to ExcelMetricZevra TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$407.54M$2.50B$5.70B$10.26BDividend YieldN/A57.22%5.72%4.60%P/E Ratio-34.5723.1675.8826.53Price / Sales6.57527.70492.67165.78Price / CashN/A27.5625.8129.90Price / Book9.815.2612.836.32Net Income-$105.51M$32.95M$3.28B$270.12M7 Day Performance-11.57%-0.55%0.17%2.12%1 Month Performance-23.01%3.79%4.54%6.31%1 Year Performance-6.68%-3.14%68.32%25.51% Zevra Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZVRAZevra Therapeutics2.9944 of 5 stars$7.26+0.4%$23.71+226.6%-7.9%$407.54M$62.02M-34.5720Analyst DowngradeHigh Trading VolumeADPTAdaptive Biotechnologies3.5349 of 5 stars$12.85-1.3%$12.38-3.7%+183.7%$1.98B$178.96M-15.67790Positive NewsRXRXRecursion Pharmaceuticals2.3 of 5 stars$4.61+2.0%$7.25+57.3%-27.4%$1.96B$58.84M-2.59400ARQTArcutis Biotherapeutics2.3386 of 5 stars$17.15+5.8%$19.80+15.5%+58.8%$1.94B$196.54M-22.87150TVTXTravere Therapeutics2.9675 of 5 stars$21.64+2.3%$33.43+54.5%+70.7%$1.89B$233.18M-10.61460High Trading VolumeDYNDyne Therapeutics3.9178 of 5 stars$14.22+7.4%$34.07+139.6%-62.2%$1.88BN/A-3.68100Positive NewsBEAMBeam Therapeutics3.0305 of 5 stars$20.88+12.6%$48.45+132.1%-19.1%$1.88B$63.52M-4.64510Analyst DowngradeSRPTSarepta Therapeutics4.412 of 5 stars$18.71+1.4%$43.50+132.5%-86.0%$1.80B$2.48B-21.511,372Positive NewsAnalyst ForecastIMCRImmunocore2.0011 of 5 stars$37.20+5.5%$56.89+52.9%+2.6%$1.78B$310.20M-93.00320Positive NewsHigh Trading VolumeMESOMesoblast1.7997 of 5 stars$14.39+6.4%$18.00+25.1%+148.6%$1.73B$17.20M0.0080High Trading VolumeAPGEApogee Therapeutics2.8841 of 5 stars$37.87+2.0%$97.29+156.9%-28.3%$1.71BN/A-9.1791Positive News Related Companies and Tools Related Companies Adaptive Biotechnologies Alternatives Recursion Pharmaceuticals Alternatives Arcutis Biotherapeutics Alternatives Travere Therapeutics Alternatives Dyne Therapeutics Alternatives Beam Therapeutics Alternatives Sarepta Therapeutics Alternatives Immunocore Alternatives Mesoblast Alternatives Apogee Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZVRA) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersWhat a Former CIA Agent Knows About the Coming Collapse This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zevra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zevra Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ZVRA Stock Alerts